H S Sader

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. ncbi Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:281-8. 2002
  2. ncbi Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 56:367-72. 2006
  3. ncbi Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus
    Helio S Sader
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 73:212-4. 2012
  4. ncbi Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 55:S181-6. 2012
  5. ncbi Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 67:1170-5. 2012
  6. ncbi Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:1619-23. 2012
  7. ncbi Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients
    Maria Cecilia S Freitas
    Department of Medicine, Division of Nephrology, Universidade Federal de Sao Paulo, Hospital do Rim e Hipertensao, Brazil
    BMC Infect Dis 6:133. 2006
  8. ncbi Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers
    H S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    J Chemother 20:28-32. 2008
  9. ncbi Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Int J Infect Dis 13:291-5. 2009
  10. ncbi Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp
    Helio S Sader
    JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:380-4. 2005

Collaborators

Detail Information

Publications125 found, 100 shown here

  1. ncbi Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:281-8. 2002
    ..National and international surveillance programs as a guide to focusing intervention strategies should assist in the control of escalating antimicrobial resistance in this geographic area...
  2. ncbi Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 56:367-72. 2006
    ..The escalating occurrence (0.35%) of serine carbapenemases could compromise the role of carbapenems and other beta-lactams in USA clinical practice although observed in only a few locations to date...
  3. ncbi Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus
    Helio S Sader
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 73:212-4. 2012
    ..In summary, daptomycin exhibited species-specific activity among CoNS, especially versus S. sciuri. No correlation between decreased susceptibility to daptomycin and the glycopeptides tested was observed...
  4. ncbi Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 55:S181-6. 2012
    ..The results also indicate that ceftaroline is highly active against MSSA and MRSA isolated from US medical centers, independent of patient age group...
  5. ncbi Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 67:1170-5. 2012
    ..We evaluated the activity of BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)...
  6. ncbi Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:1619-23. 2012
    ..12/2 μg/ml). Compared with other antibiotics in use for the treatment of ABSSSI, BC-3781 displayed the lowest MICs and only a minimal potential for cross-resistance with other antimicrobial classes...
  7. ncbi Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients
    Maria Cecilia S Freitas
    Department of Medicine, Division of Nephrology, Universidade Federal de Sao Paulo, Hospital do Rim e Hipertensao, Brazil
    BMC Infect Dis 6:133. 2006
    ..The first reports of VRE isolation were from hemodialysis patients. However, to date, VRE fecal colonization rates as well as associated risk factors in kidney transplant patients have not yet been established in prospective studies...
  8. ncbi Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers
    H S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    J Chemother 20:28-32. 2008
    ..Resistance rates to oxacillin and levofloxacin were generally elevated, especially when an intravenous catheter was the source of infection...
  9. ncbi Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Int J Infect Dis 13:291-5. 2009
    ..In the present study, we evaluated the antimicrobial susceptibility patterns of S. aureus causing BSI in dialysis patients compared to those causing BSI in other patient populations...
  10. ncbi Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp
    Helio S Sader
    JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:380-4. 2005
    ..The role of combination antimicrobial therapy in the treatment of severe infections caused by multidrug-resistant P. aeruginosa and Acinetobacter spp. should be further evaluated to maximize favourable clinical outcomes...
  11. ncbi Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003
    H S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 17:477-83. 2005
    ..The results of this study showed that daptomycin continues to be very active against clinical isolates of Gram-positive cocci isolated in Europe and Latin America...
  12. ncbi Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing Streptococcus pneumoniae: selection of a surrogate testing agent
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 62:460-3. 2008
    ..No error was observed when levofloxacin was selected as the group surrogate for pneumococcal testing...
  13. ncbi Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli
    Helio S Sader
    JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:95-109. 2005
    ....
  14. ncbi Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 50:201-4. 2004
    ..Daptomycin showed a significant potency and spectrum against Gram-positive species, including multidrug-resistant strains, and may represent a reasonable therapeutic option for infections caused by these important pathogens...
  15. ncbi Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients
    H S Sader
    JMI Laboratories, North Libtery, Iowa 52314, USA
    J Chemother 20:570-6. 2008
    ..These results indicate that daptomycin has an appropriate spectrum and potency to be used for empirical coverage of Gram-positive infections (especially BSI) in cancer patients in the hospitals surveyed in the USA...
  16. ncbi Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:3162-5. 2009
    ..2% of MRSA isolates) would be categorized as vancomycin nonsusceptible by the MIC results from the Etest method if the susceptibility breakpoint was adjusted downward to < or =1 microg/ml, as suggested by clinical outcome studies...
  17. ncbi Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections
    Helio S Sader
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:89-92. 2005
    ..The cefdinir spectrum and potency were comparable or superior to other orally administered beta-lactams tested against recent (2003) clinical isolates from CA-UTI...
  18. ncbi Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program
    Helio S Sader
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, USA
    Int J Antimicrob Agents 25:57-61. 2005
    ..The emergence and dissemination of mobile MbetaL-producing isolates represent an alarming factor for increasing resistance to carbapenems in several medical centres evaluated by the SENTRY Program in Latin America...
  19. ncbi Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:283-7. 2004
    ..Only 0.5% of all 415 recent CA-SSTI pathogens were resistant to cefdinir (MIC, > or = 4 mg/L). Cefdinir showed a spectrum and potency comparable or superior to other orally administered beta-lactams (cephalexin)...
  20. ncbi Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:2171-5. 2009
    ..aureus [MRSA]), beta-hemolytic Streptococcus spp., and Enterococcus faecalis strains tested. In addition, iclaprim exhibited bactericidal activity against all S. aureus strains tested, including MRSA...
  21. ncbi IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital
    H S Sader
    Laboratorio Alerta e Laboratorio Especial de Microbiologia Clínica, Disciplina de Doencas Infecciosas e Parasitarias, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Microbiol Infect 11:73-6. 2005
    ..MBL production was detected in 36 isolates (19.7% of the entire collection; 43.9% of the imipenem-resistant isolates) and the MBLs included SPM-1-like (55.6%), VIM-2-like (30.6%) and IMP-1-like (8.3%) enzymes...
  22. ncbi Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:514-20. 2007
    ..1%) and imipenem in Spain (87.7%). Our results suggest that tigecycline represents a viable additional option for the empirical treatment of cSSSI in these countries...
  23. ncbi Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 50:2330-6. 2006
    ....
  24. ncbi Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents
    Helio S Sader
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Clin Microbiol 44:1101-4. 2006
    ..aeruginosa that exhibit contemporary resistance mechanisms would be prudent to minimize the potential for serious reporting errors...
  25. ncbi In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii
    H S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    J Chemother 17:622-7. 2005
    ..aeruginosa (IMP-16 and SPM-1-producing strains) and one A. baumannii (non-MbetaL) strain. All other strains showed indifferent interaction (variation of +/- 1 log10 CFU/ml) with any combination evaluated...
  26. ncbi Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004)
    H S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Clin Microbiol Infect 12:844-52. 2006
    ..This novel lipopeptide (daptomycin) appears to be an excellent alternative therapeutic option for serious infections caused by multidrug-resistant gram-positive organisms isolated in Europe...
  27. ncbi Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:341-4. 2007
    ....
  28. ncbi Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Expert Rev Anti Infect Ther 5:29-43. 2007
    ..g., macrolides, penicillins, tetracyclines, fluoroquinolones and trimethoprim-sulfamethoxazole)...
  29. ncbi Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:329-32. 2005
    ..Resistance to oxacillin or vancomycin did not influence daptomycin activity against S. aureus or E. faecalis...
  30. ncbi Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:5S-12S. 2007
    ....
  31. ncbi Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Clin Microbiol 45:1640-3. 2007
    ..Listed modifications were recently approved by the CLSI (M100-S17)...
  32. ncbi Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:265-73. 2005
    ..Continued resistance surveillance is critical to monitor the effectiveness of widely used parenteral antimicrobial agents such as cefepime...
  33. ncbi In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:27-32. 2007
    ....
  34. ncbi Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    BMC Infect Dis 7:29. 2007
    ..We evaluated the in vitro activity of this compound and selected comparator agents tested against clinical strains of staphylococci and enterococci collected in European medical centers in 2005...
  35. ncbi Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
    Helio S Sader
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 49:3501-12. 2005
    ....
  36. ncbi Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:4127-32. 2009
    ..02 mug/ml). The occurrence of isolates for which the vancomycin MIC was >1 microg/ml was very unusual, with no increased trend, but these organisms were usually clonal (USA100)...
  37. ncbi SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001
    Helio S Sader
    Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Infect Dis 8:25-79. 2004
    ..This report allows the evaluation of the activities numerous antimicrobial agents against clinical isolates collected in Latin American countries...
  38. ncbi Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009)
    H S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 23:200-6. 2011
    ..Decreases in daptomycin potency were not observed since EMEA approval and widespread clinical use, and emerging resistance to other compounds did not adversely influence daptomycin activity against contemporary Gram-positive species...
  39. ncbi Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:1153-5. 2008
    ..All isolates had the Panton-Valentine leukocidin genes and staphylococcal cassette chromosome mec type IV, while 67.8% of isolates displayed pulsed-field gel electrophoresis clonal type USA300-0114...
  40. ncbi Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Diagn Microbiol Infect Dis 70:412-6. 2011
    ..faecium) were detected. In conclusion, daptomycin demonstrated sustained activity against an extensive collection of clinical isolates of MRSA and VRE from numerous US medical centers over the last 6 monitored years...
  41. ncbi Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:2390-4. 2011
    ..CXA-101 and CXA-201 were very active against P. aeruginosa (MIC50, 1 μg/ml for both compounds), including imipenem-resistant strains...
  42. ncbi Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 69:223-7. 2011
    ....
  43. ncbi Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001)
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:361-4. 2003
    ..8%-91.7%). Continued resistance surveillance by various programs remain necessary to monitor the in vitro effectiveness of antimicrobial agents currently used in clinical practice...
  44. ncbi Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002)
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 47:515-25. 2003
    ..These rates of increased susceptibility could sustain and enhance the clinical activity of orally administered beta-lactams such as cefdinir...
  45. ncbi Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 36:28-32. 2010
    ....
  46. ncbi Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 66:329-31. 2010
    ..In conclusion, S. aureus strains with vancomycin MIC of 2 microg/mL showed high rates of hVISA and vancomycin tolerance. Daptomycin retained potent bactericidal activity against S. aureus with decreased susceptibility to vancomycin...
  47. ncbi Antimicrobial resistance among Gram-positive bacteria isolated in Latin American hospitals
    H S Sader
    JMI Laboratories, North, Liberty, Iowa 52317, USA
    J Chemother 21:611-20. 2009
    ..6% susceptible). In summary, daptomycin and linezolid showed excellent in vitro activity against Gram-positive organisms (12,324) collected in Latin American hospitals, including MRSA, VRE and other multidrug-resistant organisms...
  48. ncbi Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 64:1024-8. 2009
    ..The bactericidal activities of vancomycin and daptomycin were evaluated in a large collection of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia strains from nine major USA medical centres...
  49. ncbi Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007)
    H S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 21:500-6. 2009
    ..aureus, coagulase-negative staphylococci, E. faecalis and E. faecium, respectively. Daptomycin activity was not adversely influenced by resistance to oxacillin among staphylococci or to vancomycin among enterococci...
  50. ncbi Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity
    Helio S Sader
    The JONES Group JMI Laboratories, Inc, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 48:3112-8. 2004
    ..Kill curve experiments showed a clear pattern of bactericidal activity...
  51. ncbi Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 65:158-62. 2009
    ....
  52. ncbi Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program
    H S Sader
    Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, SP, Brazil
    Braz J Infect Dis 5:200-14. 2001
    ..Thus, regional surveillance programs are essential to guide empirical therapy and infection control measures...
  53. ncbi Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98)
    H S Sader
    Federal University of Sao Paulo, Medical School of Medecine, Sao Paulo, Sao Paulo, Brazil
    Braz J Infect Dis 4:245-54. 2000
    ..The newer fluoroquinolones show an excellent potency and spectrum against pathogens causing community acquired respiratory infections in Latin America...
  54. ncbi Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections
    M A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    J Chemother 22:304-11. 2010
    ..03/0.06 mg/l; 100.0% susceptible). These in vitro data document the activity of telavancin against contemporary Gram-positive isolates and support its clinical use for the treatment of cSSSI caused by the indicated pathogens...
  55. ncbi Antimicrobial resistance in respiratory pathogens isolated in Brazil during 1999-2000
    I A Critchley
    Focus Technologies, Inc, Herndon, Virginia, 20171 4603, USA
    Braz J Infect Dis 5:294-304. 2001
    ..Pneumoniae...
  56. ncbi Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999
    A C Gales
    University of Iowa College of Medicine, Iowa City, Iowa, USA, and Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Infect Dis 32:S104-13. 2001
    ..maltophilia isolates observed in this study emphasize the importance of local surveillance in determining the most adequate therapy for acinetobacter and S. maltophilia infections and the possible clonal, epidemic nature of occurrence...
  57. ncbi In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals
    J C Cordeiro
    Special Clinical Microbiology Laboratory, Division of Infectious Diseases, , SP, Brazil
    Braz J Infect Dis 5:130-5. 2001
    ....
  58. ncbi Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil
    H S Sader
    Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Infect Dis 5:171-6. 2001
    ..The excellent in vitro Gram-positive activity by linezolid, in this study, indicate that this compound may represent an important therapeutic option for the treatment of infections caused by these pathogens in Brazil...
  59. ncbi Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
    Jennifer M Streit
    The JONES Group/JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:307-10. 2005
    ..In summary, dalbavancin was very active against a wide spectrum of resistant Gram-positive isolates and demonstrated greater potency than vancomycin or teicoplanin...
  60. ncbi Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam
    H S Sader
    Special Clinical Microbiology Laboratory, Department of Infectious and Parasitic Diseases, Universidade Federal de Sao Paulo, Brazil
    Braz J Infect Dis 4:22-8. 2000
    ..3% to 98.2% susceptibility). In sum, piperacillin/tazobactam was more active against all Gram-negative species than the other two combinations, with the exception of A. baumannii, and showed similar activity against Gram-positive cocci...
  61. ncbi Screening of antibacterial extracts from plants native to the Brazilian Amazon Rain Forest and Atlantic Forest
    I B Suffredini
    Laboratório de Extração, Universidade Paulista, Sao Paulo, SP, Brasil
    Braz J Med Biol Res 37:379-84. 2004
    ..The most active fractions are being fractionated to identify their active substances. Higher concentrations of other extracts are currently being evaluated against the same microorganisms...
  62. ncbi Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
    M A Pfaller
    Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa, USA
    Antimicrob Agents Chemother 44:747-51. 2000
    ..4 to 100% susceptible). Isolates from Canada and Latin America were generally more susceptible to both triazoles than U.S. isolates were. Continued surveillance appears necessary to detect these important changes...
  63. ncbi Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program
    A C Gales
    Universidade Federal de Sao Paulo, Division of Infectious Diseases, Department of Medicine, Sao Paulo, Brazil
    J Chemother 16:323-8. 2004
    ..5%) and varied widely (10.0 to 48.9%) among the monitored Latin American medical centers. Mupirocin resistance rates appear to be increasing and routine monitoring for potential resistance seems prudent...
  64. ncbi Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program
    D M Johnson
    The JONES Group/JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:373-6. 2003
    ..It is apparent from this investigation that many commonly prescribed empiric treatments remain viable therapeutic options for CARTI caused by these two Gram-negative respiratory tract pathogens...
  65. ncbi Ability of Latin America laboratories to detect antimicrobial resistance patterns: experience of the SENTRY Antimicrobial Surveillance Program (1997-2000)
    Rodrigo E Mendes
    Special Laboratory of Clinical Microbiology Federal University of São Paulo, SP, Brazil
    Braz J Infect Dis 7:282-9. 2003
    ....
  66. ncbi Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:273-80. 2002
    ..In summary, resistance to most antimicrobial agents for a number of species implicated in bacteremia, especially among Gram-negative rods, has reached worrisome levels and continues to increase...
  67. ncbi Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 63:440-6. 2009
    ....
  68. ncbi Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000)
    Ana C Gales
    Division of Infectious Diseases, Universidade Federal de, Sao Paulo, SP, Brazil
    Diagn Microbiol Infect Dis 44:289-99. 2002
    ..Carbapenem-resistant P. aeruginosa, ciprofloxacin-resistant E. coli, ESBL-producing K. pneumoniae constitute serious problem in this geographic region...
  69. ncbi Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol
    R N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Chemother 17:593-600. 2005
    ..This high volume international survey indicates potential therapeutic roles for dalbavancin against many troublesome resistant Gram-positive phenotypes...
  70. ncbi Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection
    A R Marra
    Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Disciplina de Doencas Infecciosas e Parasitarias, Rua Botucatu, 743, 7 andar, Vila Clementino, CEP 04023 062, Sao Paulo, SP, Brazil
    Int J Infect Dis 10:56-60. 2006
    ..For hospitals with a high prevalence of strains producing this enzyme, there is no reference material to show whether the use of the E-test method for their detection, which can be quite expensive, is actually required...
  71. ncbi Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study
    H S Sader
    Division of Infectious Diseases, Federal University of Sao Paulo, Rua Botucatu, 740, Sao Paulo SP, 04023 063 Brazil
    Braz J Infect Dis 5:21-31. 2001
    ..These results define the role of quinupristin/dalfopristin in Latin American medical centers and provide a benchmark for future in vitro comparisons...
  72. ncbi In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America
    Ana C Gales
    Department of Medicine, Division of Infectious Diseases, University of Sao Paulo, Rua Leandro Dupret 188, Sao Paulo, Brazil
    Braz J Infect Dis 9:348-56. 2005
    ..The in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluated in comparison with tetracycline and other antimicrobial agents...
  73. ncbi Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
    Jennifer M Streit
    The JONES Group/JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IW 52317, USA
    Int J Antimicrob Agents 24:111-8. 2004
    ..Cefepime and the carbapenems (imipenem or meropenem) for Gram-negative isolates and linezolid for Gram-positive isolates, provided the broadest spectrum of in vitro activity against contemporary ICU pathogens in North America...
  74. ncbi Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 54:157-64. 2006
    ..Although resistance has emerged in many epidemiologically distinct strains, clonal dissemination seems to be a key contributing factor for increasing resistance to fluoroquinolones among pneumococci in this nation...
  75. ncbi Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002
    C Mendes
    Fleury Medical Diagnostic Centre, Sao Paulo, Brazil
    Clin Microbiol Infect 10:521-6. 2004
    ..Levofloxacin, a fluoroquinolone prescribed widely for respiratory tract infections, continued to show potent activity against key respiratory pathogens...
  76. ncbi Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004)
    P R Rhomberg
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 17:459-69. 2005
    ....
  77. ncbi In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals
    A O Reis
    Division of Infectious Diseases, , Rua Botucatu 740, , SP 04023-063, Brazil
    Braz J Infect Dis 5:243-51. 2001
    ..faecium and E. faecalis among Brazilian hospitals. The results of this study indicate that linezolid is an appropriate therapeutic option for the treatment of vancomycin-resistant enterococci infections in Brazil...
  78. ncbi Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada
    Michael A Pfaller
    University of Iowa College of Medicine, Iowa City, IA, USA
    Int J Antimicrob Agents 35:282-7. 2010
    ..Fusidic acid was equally active against community-acquired MRSA and linezolid-resistant staphylococci. Fusidic acid exhibited equal or greater potency against staphylococci compared with vancomycin, daptomycin and linezolid...
  79. ncbi Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:181-6. 2005
    ..Serious infections in nosocomial environments should benefit from tigecycline use among the investigational phase 3 agents focused toward resistant strains...
  80. ncbi Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)
    Paul R Rhomberg
    The JONES Group/JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:273-81. 2004
    ..and Acinetobacter baumannii isolates. Continued surveillance of the carbapenem class and other broad-spectrum agents is warranted to monitor activity against pathogens causing serious infections in hospitalized patients...
  81. ncbi Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program
    Thomas R Fritsche
    Jones Microbiology Institute Laboratories, North Liberty, IA 52317, USA
    Clin Infect Dis 41:S276-8. 2005
    ....
  82. ncbi Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital
    Ana C Gales
    Laboratório ALERTA, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 45:77-9. 2003
    ..This manuscript reports the first appearance of an IMP-like metallo-beta-lactamase encountered in a clinical isolate of A. baumannii from a Brazilian teaching hospital...
  83. ncbi Integron carrying a novel metallo-beta-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6')-30/aac(6')-Ib': report from the SENTRY Antimicrobial Surveillance Program
    Rodrigo E Mendes
    Disciplina de Doencas Infecciosas e Parasitarias, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Antimicrob Agents Chemother 48:4693-702. 2004
    ..36 microM(-1) . s(-1)). This report further emphasizes the spread of metallo-beta-lactamase genes and their close association with various aminoglycoside resistance genes...
  84. ncbi Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli
    Helio S Sader
    The JONES Group/JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:547-50. 2003
    ....
  85. ncbi Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:203-8. 2005
    ..aeruginosa) isolated from ICU patients and may represent an excellent option for the treatment of infections in this clinical environment...
  86. ncbi Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?
    Soraya S Andrade
    Laboratório Especial de Microbiologia Clínica, Universidade Federal de Sao Paulo, 04025 010 São Paulo, SP, Brazil
    Mem Inst Oswaldo Cruz 101:741-8. 2006
    ..Our results highlight the need for developing specific CA-UTI guidelines in geographic regions where elevated resistance to new and old compounds may influence prescribing decisions...
  87. ncbi Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis
    Ana C Gales
    Laboratório ALERTA, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Int J Antimicrob Agents 27:300-2. 2006
    ..Our findings emphasise the importance of optimal dosage of linezolid to prevent the emergence of resistance...
  88. ncbi Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres
    A C Gales
    Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Microbiol Infect 11:95-100. 2005
    ..and Listeria spp. Dalbavancin may provide an important therapeutic option for Gram-positive infections, excluding those caused by enterococci with VanA-type resistance...
  89. ncbi Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program
    Tamara R Anderegg
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 26:13-21. 2005
    ..63DDD/100 patient days (a 50% increase since 2002), and indicates the important role of hospital hygiene practice in preventing the dissemination of oxazolidinone resistances, should they be detected...
  90. ncbi Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms
    Jennifer M Streit
    The JONES Group/JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Antimicrob Chemother 53:669-74. 2004
    ..CONCLUSIONS: Daptomycin exhibited excellent in vitro activity against a wide spectrum of Gram-positive organisms and may represent a therapeutic option for infections caused by multidrug-resistant pathogens worldwide...
  91. ncbi Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Microb Drug Resist 12:223-30. 2006
    ....
  92. ncbi Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007)
    Ronald N Jones
    JMI Laboratories North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 65:331-4. 2009
    ..Resistance surveillance programs should be sustained to document emerging resistance patterns of old and newer agents for difficult-to-treat pathogens such as P. aeruginosa...
  93. ncbi Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital
    Rodrigo E Mendes
    Laboratório Especial de Microbiologia Clínica and Laboratório ALERTA, Division of Infectious Disease, Federal University of Sao Paulo, Sao Paulo, Brazil
    Antimicrob Agents Chemother 51:2611-4. 2007
    ..This report describes the ability of nonfermentative nosocomial pathogens to acquire and disseminate antimicrobial resistance determinants...
  94. ncbi Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America
    Ana Cristina Gales
    Laboratório Especial de Microbiologia Clínica and Laboratório ALERTA, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Microb Drug Resist 10:286-91. 2004
    ....
  95. ncbi Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001)
    Alan H Mutnick
    The JONES Group/JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 53:290-6. 2004
    ....
  96. ncbi Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests
    Ronald N Jones
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 56:1047-52. 2005
    ..CONCLUSIONS: PPI-0903M was generally bactericidal against tested species, and the MIC results were stable across numerous susceptibility test condition changes...
  97. ncbi Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers
    Ana C Gales
    Division of Infectious Diseases, Department of Medicine, Universidade Federal de Sao Paulo, Sao Paulo, SP 04025 010, Brazil
    Diagn Microbiol Infect Dis 60:421-7. 2008
    ..9% susceptible) was as active as imipenem. This study demonstrated the sustained potency of tigecycline against contemporary clinically relevant Gram-positive and Gram-negative pathogens; tigecycline resistance was rare (0.3%)...
  98. ncbi In71, an Enterobacter cloacae blaVIM-1-carrying integron related to In70.2 from Italian Pseudomonas aeruginosa isolates: a SENTRY Antimicrobial Surveillance Program report
    Mariana Castanheira
    Laboratório ALERTA, Infectious Diseases Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Microb Drug Resist 13:130-4. 2007
    ....
  99. ncbi Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000)
    Ana C Gales
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
    Diagn Microbiol Infect Dis 44:313-8. 2002
    ....
  100. ncbi Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008)
    Ana C Gales
    Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Infect Dis 13:90-8. 2009
    ..Although vancomycin resistance rates in Brazil appears to be relatively low compared to those reported in the USA, VRE has emerged and rapidly disseminated in some Brazilian medical centers...
  101. ncbi The use of molecular typing to evaluate the dissemination of antimicrobial resistance among Gram-negative rods in Brazilian hospitals
    Iraci Tosin
    , Special Laboratory of Clinical Microbiology, , SC, Brazil
    Braz J Infect Dis 7:360-9. 2003
    ..We conclude that the ability to characterize organisms phenotypically and genotypically is a powerful epidemiologic tool and it provides unique information that is very important for multicenter surveillance programs...